Establishes "End-Stage Kidney Disease Prevention and Innovation Act"; appropriates $10 million.
This bill establishes the "End-Stage Kidney Disease Prevention and Innovation Act" and directs the Department of Health to create Centers on Rare Kidney Disease Research. The centers would support research on rare kidney diseases, including glomerular diseases, with an emphasis on causes, diagnosis, progression, treatment, and methods that could delay or eliminate the need for dialysis or transplant. The bill also authorizes the department to make grants and enter cooperative agreements with public and private nonprofit entities, and to create an advisory board including nephrologists, patient advocates, academic researchers, and public health experts.
The bill further requires the department to conduct a statewide study on testing, preventive care, precision medicine, and treatment for rare kidney disease. That study must examine routine urinalysis, kidney biopsy, genetic and genomic testing, APOL1 testing, barriers to access and insurance coverage, social and biological factors, treatment patterns under Medicare, Medicaid, and private insurance, access to nephrologists, efforts to slow disease progression, and patient trust in providers. The department must report its findings and recommendations to the Governor and Legislature after the act expires, and the act sunsets five years after taking effect.
The bill would create a new state research and grant program within the Department of Health focused on rare kidney disease and end-stage kidney disease prevention, and it would appropriate up to $10 million from the General Fund to support those activities. It would also establish new administrative duties for the department, including grantmaking, advisory board formation, competitive application procedures, and a formal study and reporting requirement. The measure would affect public health research institutions, nonprofit hospitals, medical schools, nephrology providers, patient organizations, and communities disproportionately affected by kidney disease, especially rural, underserved, and minority populations.
The bill appears strongly supportive of expanded public health investment in kidney disease research, prevention, and workforce development. Its structure suggests a consensus-oriented approach centered on research, education, and access, with particular attention to underserved communities and populations disproportionately affected by rare kidney disease. No committee votes or hearing transcripts were provided, so there is no recorded opposition or formal vote history to indicate broader legislative sentiment beyond the bill’s stated policy goals.
The main policy sensitivities in the bill involve how the research and grant program is targeted and evaluated. The bill specifically prioritizes minority and underserved communities, includes APOL1-related research, and bars the use of quality-adjusted life years or disability-adjusted life years in funded research when assessing populations studied, which reflects concern about disability-based discrimination in cost-effectiveness analysis. Potential points of debate could also include the $10 million appropriation, the scope of state involvement in research and fellowship support, and the bill’s reliance on cooperative agreements with selected entities, but no explicit opposition is documented in the provided materials.